Fintel reports that on January 8, 2025, BTIG downgraded their outlook for Inari Medical (NasdaqGS:NARI) from Buy to Neutral.

Terumo's solid leadership in radial access devices and expanding interventional portfolio present significant growth ...

Published results showed patients who undergo total knee arthroplasty at an altitude of 4,000 feet or higher may be at ...

Stryker's acquisition of Inari for $4.9B enhances its neurovascular portfolio and boosts revenue growth by 50bp, with minimal ...

Inari Medical (NASDAQ:NARI – Get Free Report)‘s stock had its “neutral” rating reaffirmed by Robert W. Baird in a research note issued to investors on Tuesday,Benzinga reports. They presently have a ...

Stryker (NYSE: SYK), a global leader in medical technologies, has announced its definitive agreement to acquire Inari Medical ...

Your blood type may be a window into your health. From heart disease and strokes to certain types of cancer, here's why blood ...